Tamoxifen may require metabolic activation to endoxifen for efficacy in treating hormone receptor–positive breast cancer. Dose escalation in patients with low endoxifen concentrations could enhance treatment efficacy. This approach is clinically feasible, and successfully increases endoxifen concentrations; however, it is unknown whether patients benefit from individualized tamoxifen dose escalation. Clin Cancer Res; 22(13); 3121–3. ©2016 AACR.
See related article by Fox et al., p. 3164
from Cancer via ola Kala on Inoreader http://ift.tt/29hTTFK
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου